Wu Changwu, Tan Jun, Wang Xiangyu, Qin Chaoying, Long Wenyong, Pan Yimin, Li Yuzhe, Liu Qing
Department of Neurosurgery, Xiangya Hospital Central-South University Changsha Hunan China.
Department of Neurosurgery, Devision of Experimental Neurosurgery University of Heidelberg Heidelberg Germany.
Imeta. 2022 Dec 7;2(1):e68. doi: 10.1002/imt2.68. eCollection 2023 Feb.
Imbalance in copper homeostasis can be lethal. A recent study found that excess copper induces cell death in a way that has never been characterized before, which is dependent on mitochondrial stress and is referred to as "cuproptosis." The role of cuproptosis in tumors has not yet been elucidated. In this study, we revealed the complex and important roles of cuproptosis regulators and cuproptosis activity in tumors via a comprehensive analysis of multiomics data from more than 10,000 samples of 33 tumor types. We found that the cyclin-dependent kinase inhibitor 2A is the most frequently altered cuproptosis regulator, and the cuproptosis regulator expression is dysregulated in various tumors. Additionally, we developed a cuproptosis activity score to reflect the overall cuproptosis level. On the basis of the expression levels of cuproptosis regulators, tumors can be divided into two clusters with different cuproptosis activities and survival outcomes. Importantly, cuproptosis activity was found to be associated with the prognosis of multiple tumors and multiple tumor-related pathways, including fatty acid metabolism and remodeling of the tumor microenvironment. Furthermore, cuproptosis increased the sensitivity to multiple drugs and exhibited potential to predict the outcome of immunotherapy. We also comprehensively identified cuproptosis-related microRNAs, long noncoding RNAs, and transcription factors. We provided the code corresponding to the results of this study in GitHub (https://github.com/Changwuuu/Cuproptosis-pancancer.git) for reference. In summary, this study reveals important molecular and clinical characteristics of cuproptosis regulators and cuproptosis activity in tumors, and suggests the use of cuproptosis as a promising tumor therapeutic approach. This study provides an important reference point for future cuproptosis-related research.
Front Oncol. 2022-10-27
Immunol Rev. 2024-1
Medicine (Baltimore). 2023-4-7
J Cancer Res Clin Oncol. 2024-8-5
Int J Med Sci. 2025-6-12
Funct Integr Genomics. 2025-3-1
Imeta. 2022-8-1
Hum Exp Toxicol. 2022
BMC Gastroenterol. 2022-4-16
Science. 2022-3-18
Nat Rev Cancer. 2022-2